Item 1.01 Entry into a Material Definitive Agreement.

On September 2, 2022, Yubo International Biotech Limited, a New York corporation (the "Company"), entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with World Precision Medicine Technology Limited (the "Purchaser"), pursuant to which the Company agreed to sell and issue to the Purchaser an aggregate of 1,638,458 shares (the "Shares") of Class A Common Stock, par value $0.001 per share, of the Company, at $0.50 per share, for a gross proceed of $819,229.

The offering and sale of the Shares have been registered under the Securities Act of 1933, as amended, pursuant to the Company's Registration Statement on Form S-1 (Registration No. 333-255805), which was declared effective by the U.S. Securities and Exchange Commission on July 29, 2022.

The foregoing summary of the Securities Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full terms of the Securities Purchase Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 1.01.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits.



Exhibit No.                               Description
   10.1         Securities Purchase Agreement, dated September 2, 2022, by and
              between the Company and the Purchaser (certain portions of this
              exhibit containing personally identifiable information have been
              redacted)
    104       Cover Page Interactive Data File (embedded within the Inline XBRL
              document)





2

© Edgar Online, source Glimpses